KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:待检查

Adverse events associated with immune checkpoint inhibitors in cervical cancer: A systematic review and meta-analysis of randomized controlled trials.

Fenghua Liu, Lili Wang, Qiao Sun, Shuai Jing, Yue Yue, Weiwei Zhang

Eur J Obstet Gynecol Reprod Biol 324 115263

PMID42320227
PMCID-
DOI10.1016/j.ejogrb.2026.115263
发表日期2026-06-19
AI 判定该论文不进入自动 KM 提取:This record is a systematic review and meta-analysis, not a primary Phase III randomized controlled clinical trial. It synthesizes data from multiple trials, which are excluded per the classification instructions.
摘要

摘要

OBJECTIVES: This study aimed to assess the incidence of adverse events (AEs) related to immune checkpoint inhibitors (ICIs) in cervical cancer (CC) therapy and provide clinical recommendations to ensure their safe, rational, and effective use. METHODS: This systematic review was registered on PROSPERO under the registration number CRD420251133016. A systematic search following the PICO guidelines was conducted across PubMed (n = 71), Embase (n = 321), Web of Science (n = 174), and the Cochrane Library (n = 291) databases from May 30, 2026, without any language limitations. Inclusion criteria encompassed randomized controlled phase III trials (RCTs) that reported treatment-related adverse events (trAEs) or immune-related adverse events (irAEs) in the context of ICI-based cervical cancer treatments. RESULTS: Five RCTs involving a total of 3,302 patients satisfied the eligibility criteria. When compared to the control group consisting of standard chemoradiotherapy or chemotherapy, the incidence of trAEs of any grade or treatment-related death was not found to be significantly associated with immune checkpoint inhibitors (RR: 1.00, [95 % CI] 0.99 to 1.01, p = 0.98; RR: 1.44, [95 % CI] 0.69 to 2.97, p = 0.33, respectively). But, the incidence of grade 3 or higher trAEs, irAEs of any grade, grade 3 or higher irAEs, and treatment-related discontinuation was significantly associated with immune checkpoint inhibitors compared with placebo (RR: 1.07, [95 % CI] 1.03 to 1.11, p = 0.001; RR: 2.80, [95 % CI] 1.71 to 4.58, p < 0.001; RR: 4.60, [95 % CI] 2.70 to 7.84, p < 0.001; RR: 1.41, [95 % CI] 1.08 to 1.84p = 0.01, respectively). CONCLUSION: This meta-analysis summarizes the AE profile of ICIs in cervical cancer treatment. These results indicate that ICI-based regimens exhibit comparable overall general toxicity to standard cervical cancer therapies. Nevertheless, the increased immune-related and high-grade toxicities constitute unique safety risks of ICIs. Close clinical monitoring and targeted toxicity management are therefore essential to ensure the safe and stable clinical application of ICIs in cervical cancer treatment.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。